These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 27241541)

  • 1. Comparison of Asymmetric Dimethylarginine Levels Between Stages Three, Four, and Five Non-dialysis of Chronic Kidney Disease.
    Asmarawati TP; Widodo ; Thaha M; Aditiawardana ; Mardiana N; Ardhany AR; Tjempakasari A; Santoso D; Pranawa ; Irwanadi C
    Acta Med Indones; 2016 Jan; 48(1):28-34. PubMed ID: 27241541
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Significance of the factors of hypoxia and endothelial dysfunction in kidney injury in the presence of obesity].
    Galiamov MG; Saginova EA; Severova MM; Samokhodskaia LM; Krasnova TN; Sholomova VI; Sorokin IuD; Mukhin NA
    Ter Arkh; 2013; 85(6):31-7. PubMed ID: 23866596
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asymmetric dimethylarginine and progression of chronic kidney disease: a one-year follow-up study.
    Eiselt J; Rajdl D; Racek J; Vostrý M; Rulcová K; Wirth J
    Kidney Blood Press Res; 2014; 39(1):50-7. PubMed ID: 24923294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating angiopoietin-2 levels increase with progress of chronic kidney disease.
    David S; Kümpers P; Lukasz A; Fliser D; Martens-Lobenhoffer J; Bode-Böger SM; Kliem V; Haller H; Kielstein JT
    Nephrol Dial Transplant; 2010 Aug; 25(8):2571-6. PubMed ID: 20179005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring asymmetric dimethylarginine (ADMA) in CKD: a comparison between enzyme-linked immunosorbent assay and liquid chromatography-electrospray tandem mass spectrometry.
    Pecchini P; Malberti F; Mieth M; Quinn R; Tripepi G; Mallamaci F; Maas R; Zoccali C; Ravani P
    J Nephrol; 2012; 25(6):1016-22. PubMed ID: 22322824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating levels of asymmetric dimethylarginine are an independent risk factor for left ventricular hypertrophy and predict cardiovascular events in pre-dialysis patients with chronic kidney disease.
    Shi B; Ni Z; Zhou W; Yu Z; Gu L; Mou S; Fang W; Wang Q; Cao L; Yan Y; Qian J
    Eur J Intern Med; 2010 Oct; 21(5):444-8. PubMed ID: 20816602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Comparison between two equations to estimated glomerular filtration rate].
    Esteve Poblador S; Gorriz Pintado S; Ortuño Alonso M
    Rev Clin Esp; 2012 Feb; 212(2):75-80. PubMed ID: 22119342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gender differences in the relationships between chronic kidney disease, asymmetric dimethylarginine, and sleep quality: The HEIJO-KYO cohort.
    Obayashi K; Kurumatani N; Saeki K
    Nitric Oxide; 2018 Sep; 79():25-30. PubMed ID: 29983400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Could mean platelet volume be a promising biomarker of progression of chronic kidney disease?
    Ju HY; Kim JK; Hur SM; Woo SA; Park KA; Park MY; Choi SJ; Hwang SD
    Platelets; 2015; 26(2):143-7. PubMed ID: 24679226
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Creatinine- vs. cystatin C-based equations compared with 99mTcDTPA scintigraphy to assess glomerular filtration rate in chronic kidney disease.
    Trimarchi H; Muryan A; Martino D; Toscano A; Iriarte R; Campolo-Girard V; Forrester M; Pomeranz V; Fitzsimons C; Lombi F; Young P; Raña MS; Alonso M
    J Nephrol; 2012; 25(6):1003-15. PubMed ID: 22322818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for chronic kidney disease do not influence the serum levels of asymmetric dimethylarginine in HIV-1-infected patients without significant renal disease.
    Szymanek-Pasternak A; Szymczak A; Zalewska M; Małyszczak K; Knysz B
    Pol Arch Med Wewn; 2016 Aug; 126(9):672-680. PubMed ID: 27535326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Level of asymmetric dimethylarginine and carotid atherosclerosis in patients with chronic kidney disease.
    Zhang WR; Hou FF; Ning JP; Yang XB; Wu Q; Tao LJ; Chen BM; Li HY; Chang L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):621-8. PubMed ID: 17062918
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arginine, dimethylated arginine and homoarginine in relation to cardiovascular risk in patients with moderate chronic kidney disease.
    Hov GG; Aasarød KI; Sagen E; Åsberg A
    Clin Biochem; 2015 Jul; 48(10-11):646-51. PubMed ID: 25828044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine.
    Yilmaz MI; Saglam M; Caglar K; Cakir E; Sonmez A; Ozgurtas T; Aydin A; Eyileten T; Ozcan O; Acikel C; Tasar M; Genctoy G; Erbil K; Vural A; Zoccali C
    Am J Kidney Dis; 2006 Jan; 47(1):42-50. PubMed ID: 16377384
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The relationship among asymmetric dimethylarginine (ADMA) levels, residual renal function, and left ventricular hypertrophy in continuous ambulatory peritoneal dialysis patients.
    Ebinç FA; Erten Y; Ebinç H; Paşaoğlu H; Demirtaş C; Taçoy G; Mutluay R; Koç E; Derici U; Reis KA; Bali M; Arinsoy T; Sindel S
    Ren Fail; 2008; 30(4):401-6. PubMed ID: 18569913
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Chronic Kidney Disease-Epidemiology Collaboration (CKD-EPI) equation does not improve the underestimation of Glomerular Filtration Rate (GFR) in people with diabetes and preserved renal function.
    MacIsaac RJ; Ekinci EI; Premaratne E; Lu ZX; Seah JM; Li Y; Boston R; Ward GM; Jerums G
    BMC Nephrol; 2015 Dec; 16():198. PubMed ID: 26630928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic renal impairment and DDAH2-1151 A/C polymorphism determine ADMA levels in type 2 diabetic subjects.
    Marra M; Marchegiani F; Ceriello A; Sirolla C; Boemi M; Franceschi C; Spazzafumo L; Testa I; Bonfigli AR; Cucchi M; Testa R
    Nephrol Dial Transplant; 2013 Apr; 28(4):964-71. PubMed ID: 23129820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.
    Nanayakkara PW; Kiefte-de Jong JC; ter Wee PM; Stehouwer CD; van Ittersum FJ; Olthof MR; Teerlink T; Twisk JW; van Guldener C; Smulders YM
    Am J Kidney Dis; 2009 Jan; 53(1):41-50. PubMed ID: 18786751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Plasma asymmetric dimethylarginine and its association with some of cardiovascular disease risk factors in chronic kidney disease.
    Quoc Hoang TA; Tam V; Thang HV
    Med J Malaysia; 2019 Jun; 74(3):209-214. PubMed ID: 31256175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Chronic Kidney Disease Epidemiology Collaboration cystatin C (CKD-EPI-CysC) equation has an independent prognostic value for overall survival in newly diagnosed patients with symptomatic multiple myeloma; is it time to change from MDRD to CKD-EPI-CysC equations?
    Terpos E; Christoulas D; Kastritis E; Katodritou E; Pouli A; Michalis E; Papassotiriou I; Dimopoulos MA;
    Eur J Haematol; 2013 Oct; 91(4):347-55. PubMed ID: 23829647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.